Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

This study examines how well the combination of an immunotherapy drug (anti-PD-1/PD-L1) and an anti-VEGF drug (which blocks tumor blood vessel growth) works in patients with advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. **You may be eligible if...** - You are 18 or older with advanced HCC that is inoperable or has spread - You have at least one measurable tumor that has not been treated locally - Your liver function is classified as Child-Pugh A (well-preserved) - Your cancer stage is Barcelona B or C - You are in good physical condition (ECOG 0 or 1) **You may NOT be eligible if...** - Your liver function is significantly impaired - You have had prior treatments that would exclude you per study criteria - You are pregnant or need contraception but refuse to use it Talk to your doctor to see if this trial is right for you.